Latest Insider Transactions at Organogenesis Holdings Inc. (ORGO)
This section provides a real-time view of insider transactions for Organogenesis Holdings Inc. (ORGO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Organogenesis Holdings Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Organogenesis Holdings Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 16
2024
|
Robert Cavorsi Vice President, Strategy |
SELL
Payment of exercise price or tax liability
|
Direct |
317
-0.23%
|
$951
$3.09 P/Share
|
|
Apr 01
2024
|
Gary S. Gillheeney President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,113
-0.43%
|
$20,226
$2.8 P/Share
|
|
Apr 01
2024
|
Antonio S. Montecalvo Vice President, Health Policy |
SELL
Payment of exercise price or tax liability
|
Direct |
1,752
-1.03%
|
$3,504
$2.8 P/Share
|
|
Apr 01
2024
|
Brian Grow Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,977
-0.38%
|
$3,954
$2.8 P/Share
|
|
Apr 01
2024
|
Lori Freedman Chief Admin. and Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,974
-0.42%
|
$3,948
$2.8 P/Share
|
|
Apr 01
2024
|
Patrick Bilbo Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,497
-0.31%
|
$4,994
$2.8 P/Share
|
|
Mar 28
2024
|
Patrick Bilbo Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
152,250
+15.8%
|
$152,250
$1.18 P/Share
|
|
Feb 21
2024
|
Jon L Giacomin Director |
BUY
Grant, award, or other acquisition
|
Direct |
51,020
+26.35%
|
-
|
|
Feb 21
2024
|
Michele Ilene Korfin Director |
BUY
Grant, award, or other acquisition
|
Direct |
51,020
+26.62%
|
-
|
|
Feb 21
2024
|
Patrick Bilbo Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
187,318
+22.12%
|
-
|
|
Feb 21
2024
|
Gary S. Gillheeney President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
685,131
+22.48%
|
-
|
|
Feb 21
2024
|
Lori Freedman Chief Admin. and Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
153,061
+24.52%
|
-
|
|
Feb 21
2024
|
Brian Grow Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
173,469
+24.91%
|
-
|
|
Feb 21
2024
|
David Francisco Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
160,350
+27.21%
|
-
|
|
Feb 21
2024
|
Antonio S. Montecalvo Vice President, Health Policy |
BUY
Grant, award, or other acquisition
|
Direct |
43,732
+20.46%
|
-
|
|
Feb 21
2024
|
Prathyusha Duraibabu Director |
BUY
Grant, award, or other acquisition
|
Direct |
51,020
+25.55%
|
-
|
|
Feb 21
2024
|
Arthur S Leibowitz Director |
BUY
Grant, award, or other acquisition
|
Direct |
51,020
+21.38%
|
-
|
|
Feb 21
2024
|
Michael Joseph Driscoll Director |
BUY
Grant, award, or other acquisition
|
Direct |
51,020
+26.39%
|
-
|
|
Feb 21
2024
|
Gilberto Quintero Director |
BUY
Grant, award, or other acquisition
|
Direct |
51,020
+26.62%
|
-
|
|
Feb 16
2024
|
Antonio S. Montecalvo Vice President, Health Policy |
SELL
Payment of exercise price or tax liability
|
Direct |
719
-0.57%
|
$2,157
$3.48 P/Share
|
|
Feb 16
2024
|
Patrick Bilbo Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
791
-0.17%
|
$2,373
$3.48 P/Share
|
|
Feb 16
2024
|
David Francisco Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
804
-0.3%
|
$2,412
$3.48 P/Share
|
|
Feb 16
2024
|
Lori Freedman Chief Admin. and Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
646
-0.2%
|
$1,938
$3.48 P/Share
|
|
Feb 16
2024
|
Gary S. Gillheeney President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,788
-0.23%
|
$11,364
$3.48 P/Share
|
|
Feb 16
2024
|
Brian Grow Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
799
-0.23%
|
$2,397
$3.48 P/Share
|
|
Feb 15
2024
|
Antonio S. Montecalvo Vice President, Health Policy |
SELL
Payment of exercise price or tax liability
|
Direct |
9,909
-3.65%
|
$29,727
$3.68 P/Share
|
|
Feb 15
2024
|
Patrick Bilbo Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
29,533
-2.96%
|
$88,599
$3.68 P/Share
|
|
Feb 15
2024
|
David Francisco Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
22,479
-3.89%
|
$67,437
$3.68 P/Share
|
|
Feb 15
2024
|
Lori Freedman Chief Admin. and Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
25,159
-3.69%
|
$75,477
$3.68 P/Share
|
|
Feb 15
2024
|
Gary S. Gillheeney President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
87,213
-2.49%
|
$261,639
$3.68 P/Share
|
|
Feb 15
2024
|
Brian Grow Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
22,084
-2.99%
|
$66,252
$3.68 P/Share
|
|
Jan 10
2024
|
Albert Erani > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
35,944
-0.03%
|
$143,776
$4.28 P/Share
|
|
Jan 09
2024
|
Albert Erani > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
395,842
-0.33%
|
$1,583,368
$4.37 P/Share
|
|
Apr 12
2023
|
Albert Erani > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
50,000
-0.04%
|
$100,000
$2.07 P/Share
|
|
Apr 01
2023
|
Patrick Bilbo Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,678
-0.53%
|
$5,356
$2.13 P/Share
|
|
Apr 01
2023
|
Lori Freedman Chief Admin. and Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,339
-0.68%
|
$4,678
$2.13 P/Share
|
|
Apr 01
2023
|
Gary S. Gillheeney President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,470
-0.36%
|
$12,940
$2.13 P/Share
|
|
Apr 01
2023
|
Antonio S. Montecalvo Vice President, Health Policy |
SELL
Payment of exercise price or tax liability
|
Direct |
2,097
-1.51%
|
$4,194
$2.13 P/Share
|
|
Apr 01
2023
|
Brian Grow Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,408
-0.64%
|
$4,816
$2.13 P/Share
|
|
Feb 22
2023
|
Michele Ilene Korfin Director |
BUY
Grant, award, or other acquisition
|
Direct |
65,737
+42.31%
|
-
|
|
Feb 22
2023
|
Gilberto Quintero Director |
BUY
Grant, award, or other acquisition
|
Direct |
65,737
+42.31%
|
-
|
|
Feb 22
2023
|
Prathyusha Duraibabu Director |
BUY
Grant, award, or other acquisition
|
Direct |
65,737
+40.24%
|
-
|
|
Feb 22
2023
|
Gary S. Gillheeney President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
896,414
+33.56%
|
-
|
|
Feb 22
2023
|
David Francisco Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
242,508
+45.38%
|
-
|
|
Feb 22
2023
|
Patrick Bilbo Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
327,386
+39.33%
|
-
|
|
Feb 22
2023
|
Brian Grow Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
291,009
+43.72%
|
-
|
|
Feb 22
2023
|
Lori Freedman Chief Admin. and Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
278,884
+44.61%
|
-
|
|
Feb 22
2023
|
Antonio S. Montecalvo Vice President, Health Policy |
BUY
Grant, award, or other acquisition
|
Direct |
99,428
+41.7%
|
-
|
|
Feb 22
2023
|
Arthur S Leibowitz Director |
BUY
Grant, award, or other acquisition
|
Direct |
65,737
+32.49%
|
-
|
|
Feb 22
2023
|
Jon L Giacomin Director |
BUY
Grant, award, or other acquisition
|
Direct |
65,737
+41.78%
|
-
|